New cancer combo drug tested in tiny safety study
NCT ID NCT06894771
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested the safety of an experimental drug called MK-4700, given alone or with the approved immunotherapy Keytruda, in 5 people with advanced solid tumors that had stopped responding to other treatments. The main goal was to find a safe dose and see how the body handles the drug. Because it's a Phase 1 trial with very few participants, it cannot tell us if the drug works against cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MK-4700 (an experimental biologic) and pembrolizumab (Keytruda)
What this could lead to
If successful, this could point toward a safe dose of MK-4700 for further testing in larger cancer trials.
What could go wrong
This is a very early, small study (only 5 people) focused on safety, not effectiveness. The drug may not work or could have serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0102)
Québec, Quebec, G1J 1Z4, Canada
-
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0301)
Hackensack, New Jersey, 07601, United States
-
NEXT Oncology ( Site 0300)
San Antonio, Texas, 78229, United States
-
Princess Margaret Cancer Center ( Site 0101)
Toronto, Ontario, M5G 2M9, Canada
-
Rabin Medical Center ( Site 0202)
Petah Tikva, 4941492, Israel
-
Rambam Health Care Campus ( Site 0201)
Haifa, 3109601, Israel
-
Sheba Medical Center ( Site 0200)
Ramat Gan, 5265601, Israel